These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells. Ohnota H; Kobayashi M; Koizumi T; Katsuno K; Sato F; Aizawa T Biochem Pharmacol; 1995 Jan; 49(2):165-71. PubMed ID: 7840793 [TBL] [Abstract][Full Text] [Related]
10. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. I. Secretory and cationic aspects. Malaisse WJ; Sato F Gen Pharmacol; 1995 Oct; 26(6):1313-8. PubMed ID: 7590125 [TBL] [Abstract][Full Text] [Related]
11. Determination of the nateglinide polymorphism structure and the drug effect. Li G; Chen JY; Lü GL; Xu QW Yao Xue Xue Bao; 2005 Oct; 40(10):958-60. PubMed ID: 16408818 [No Abstract] [Full Text] [Related]
12. Synergistic effects of hypoglycaemic sulphonylureas and antibiotic ionophores upon calcium translocation. Couturier E; Malaisse WJ Br J Pharmacol; 1980; 71(1):315-20. PubMed ID: 6781574 [TBL] [Abstract][Full Text] [Related]
13. [Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives]. Gao LM; Yang P; Song DQ Yao Xue Xue Bao; 2005 Dec; 40(12):1122-6. PubMed ID: 16496677 [TBL] [Abstract][Full Text] [Related]
14. Conformational analysis of the calcium complexes formed by meglitinide analogs. Lins L; Brasseur R; Malaisse WJ Res Commun Mol Pathol Pharmacol; 1995 Oct; 90(1):153-64. PubMed ID: 8581340 [TBL] [Abstract][Full Text] [Related]
15. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Misawa K; Ichikawa K; Ojima K; Hamano S; Kitamura T; Komatsu H Pharmacology; 2001 Feb; 62(2):65-72. PubMed ID: 11174074 [TBL] [Abstract][Full Text] [Related]
16. The ability of a new hypoglycaemic agent, A-4166, compared to sulphonylureas, to increase cytosolic Ca2+ in pancreatic beta-cells under metabolic inhibition. Fujitani S; Okazaki K; Yada T Br J Pharmacol; 1997 Apr; 120(7):1191-8. PubMed ID: 9105692 [TBL] [Abstract][Full Text] [Related]
17. A new crystal form of nateglinide. Li G; Su GQ; Xu QW; Zhu CQ Yao Xue Xue Bao; 2001 Jul; 36(7):532-4. PubMed ID: 12585087 [TBL] [Abstract][Full Text] [Related]
18. Nateglinide, a new agent for postprandial glucose control in type 2 diabetes. Kotapati S Conn Med; 2002 May; 66(5):269-72. PubMed ID: 12071108 [No Abstract] [Full Text] [Related]
19. Stoichiometry of calcium binding by hypoglycemic sulfonylureas. Deleers M; Brasseur R; Malaisse WJ Res Commun Chem Pathol Pharmacol; 1983 Nov; 42(2):181-201. PubMed ID: 6658185 [TBL] [Abstract][Full Text] [Related]